PMTCT program in Arua Uganda Lessons learned after 5 years of experience Experts Roundtable 23-24 June 2008 Geneva.

Slides:



Advertisements
Similar presentations
L Children living with HIV/AIDS l New HIV infections in children in 1999 l Child deaths due to HIV/AIDS in 1999 l Cumulative number of child deaths due.
Advertisements

Dr KANUPRIYA CHATURVEDI Dr. S.K. CHATURVEDI
Loss to follow-up among women in Option B+ PMTCT programme in Lilongwe, Malawi: Understanding outcomes and reasons Hannock Tweya, Salem Gugsa, Mina Hosseinipour,
Draft Generic Protocol: Measuring Impact and Effectiveness of National Programs for Prevention of Mother-To-Child HIV Transmission at Population-Level.
EMTCT Tanzania Experience 6 th Joint Biennial HIV & AIDS Sector Review Dr MD Kajoka PMTCT Coordinator.
PMTCT FAILURE: THE ROLE OF MATERNAL AND FACILITY –RELATED FACTORS ICASA Presentation 8 th to 12 th Dec 2013 Onono Maricianah 1, Elizabeth A. Bukusi 1,
1 Effect of Maternal HAART on Postnatal HIV-1 Transmission after Cessation of Extended Infant Antiretroviral Prophylaxis Taha Taha 1, Johnstone Kumwenda.
Improving Retention, Adherence, and Psychosocial Support within PMTCT Services: Implementation Workshop for Health Workers All slide illustrations by Petra.
Dr Tin Tin Sint Department of HIV/AIDS World Health Organization
Effectiveness of the National PMTCT Program in Rwanda
Designing a National PMTCT Impact Evaluation for Option B+ in Malawi Dr. Beth A. Tippett Barr, CDC-Malawi AIDS Turning the Tide Together.
PMTCT Generic Training Package Module 3 Slide 1 Specific Interventions to Prevent MTCT M O D U L E 3.
PROMISE Introduction to PROMISE Protocol May 6, 2009.
Dr. Laura Guay Vice President for Research Elizabeth Glaser Pediatric AIDS Foundation J2J Global Media Training on HIV/AIDS July 14, 2010 Vienna, Austria.
Use of Antiretroviral Drugs for Treating Pregnant Women and
Evaluating ICAP-supported Prevention of Mother to Child Transmission (PMTCT) Programs in 7 countries: Rosalind Carter, PhD Epidemiologist, PMTCT, Pediatrics.
Prevention of Mother-to-Child Transmission of HIV in Ghana
Office of Global Health and HIV (OGHH) Office of Overseas Programming & Training Support (OPATS) Maternal and Newborn Health Training Package Session 11:
THE CORE STUDY COMPARING TWO STRATEGIES FOR ENROLLING HIV-INFECTED PREGNANT WOMEN FROM ANTENATAL CARE TO CARE AND TREATMENT SERVICES IN CAMEROON: CONTINUUM.
“Getting to Zero: Thailand’s Experience with E-MTCT” Petchsri Sirinirund Advisor on HIV/AIDS Policy and Programme Department of Disease Control, Thailand.
Elimination of Mother to Child Transmission of HIV: Performance of Different Models of Care when Initiating Lifelong ART for Pregnant Women in Malawi (Option.
Pediatric HIV Care & Treatment in Uganda A Five-Day Training Course For Health Professionals.
Purpose Provide concepts and latest research findings related to prevention of mother-to-child transmission of HIV (PMTCT) for application in the workplace.
Preliminary findings of a routine PMTCT Option B+ programme in a rural district in Malawi Rebecca M. Coulborn 1, Laura Triviño Duran 1, Carol Metcalf 2,
N. Shema 1, L. Tsague 2, J.D.D. Bizimana 3, P. Mugwaneza 1, A. Lyambabaje 3, E. Munyana 2, J. Condo 3, J.C. Uwimbabazi 4, E. Rugigana 3, J. Muita 2 1-
Presenter : Dr T. G. Nematadzira on behalf of The IMPAACT PROMISE 1077BF/1077FF Team Efficacy and Safety of Two Strategies to Prevent Perinatal HIV Transmission.
PMTCT at Different Levels of Care: The Uganda Experience Dr. Saul Onyango National PMTCT Coordinator Ministry of Health 1 1.
PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV WHAT’S NEW Prepared by Dr. Debbie Carrington National HIV/AIDS Prevention & Control Programme Ministry.
Overview of HIV Prevention in Mothers, Infants, and Young Children
Prevention of Mother-to-Child Transmission of HIV infection in Sri Lanka Dr Sujatha Samarakoon Consultant Venereologist / Focal Point ECS & PMTCT – National.
PMTCT Prevention of Mother to Child Transmission Version Aug 2011.
1 Advantages and risks for a child to be exposed to the triple prophylaxis during pregnancy and breastfeeding What is the best for the child ? Pr C. Courpotin.
Supporting HIV positive mothers with infant feeding issues Group 4.
Human Resource Constraints and Roll out of more efficacious regimens for PMTCT The Zambian experience Nande Putta MD MPH Technical Assistant PMTCT & Paediatric.
Generic protocol for national population-based impact evaluation of national programs for PMTCT at 6 weeks post-partum Thu-Ha Dinh, MD., MS., US CDC/GAP.
Module II: Feeding and HIV Testing for Exposed Infants This module, we will discuss: Unit 1: Infant Feeding Guidelines Unit 2: HIV Testing and Treatment.
EARLY CHILDHOOD OUTCOMES AT THE BOTSWANA- BAYLOR CHILDREN’S CLINICAL CENTRE OF EXCELLENCE: A REPORT TO THE WHO TECHNICAL REFERENCE GROUP ON PEDIATRIC CARE.
PMTCT Presented by: Ms T. Nondanyana (PMTCT COORDINATOR) Room: 129 Tel:
Integrating PMTCT and ART N. Shaffer PMTCT/Peds TWG PEPFAR Track 1 Sept 25, 2007.
8èmes Rencontres Nord-Sud Avelin Aghokeng IRD-UMI233 & University of Montpellier I Yaoundé-Cameroon Avelin Aghokeng IRD-UMI233 & University of Montpellier.
Charles S. Kiptemas, MBChB, MPH Director South Rift Valley HIV Care & Treatment Program Kenya Medical Research Institute/Walter Reed Project Track 1 Partners.
HIV DISEASE IN PREGNANCY
Transmission of HIV from mother to fetus. - is not simply one of the major health problems today, but also a big problem in the field of human rights.
Alison Drake International AIDS Society Conference July 18, 2011 Valacyclovir suppression reduces breast milk and plasma HIV-1 RNA postpartum: results.
Mashi Study Dr T Gaolathe Botswana Harvard School of Public Health AIDS Initiative Partnership.
THE 6 TH NATIONAL SCIENTIFIC CONFERENCE ON HIV/AIDS Late maternal HIV testing, HCMC Chi K. Nguyen 1, Haily T. Pham 2, ThuVan T. Tieu 2, Chinh.
Antiretroviral treatment programme in Thyolo district, Malawi Southern Region. MSF Luxembourg & Thyolo District Health Services - Strategic information.
EMTCT in Europe. MTCT rates, UK and Ireland, CROI 2007 Poster 761, Townsend et al diagnosed women, Low rates of MTCT from diagnosed.
Human Immune Deficiency Virus Infection Dr Huda Taha Sep 2015.
PMTCT around the world Where are we? PMTCT Experts Roundtable Geneva, June 2008.
PMTCT - The Platform for integrating HIV/AIDS Services in the MCH Clinic. Bola Oyeledun, MD, MPH Track 1.0 Partners Meeting Washington DC. August 2008.
HIV Prevention in Mothers and Infants DR KANUPRIYA CHATURVEDI.
MATERNAL ANTIRETROVIRAL THERAPY AND INFANT OUTCOMES THROUGHOUT THE FIRST YEAR OF LIFE: results from the DREAM study in Dschang, Cameroon Taafo F, Doro.
Cascade of Prevention of Mother-to-Child Transmission of HIV (PMTCT) for Option B+ Transition: Findings from a Cohort of a Nationally Representative Sample.
Adults living with HIV (15+) (thousands) [5] Children living with HIV (0-14) (thousands) [5] Pregnant.
Diagram: Four stages of PMTCT Primary prevention of HIV Antenatal Care Labour and delivery Postnatal Care.
BARRIERS TO AND FACILITATORS FOR RETENTION OF MOTHER BABY-PAIRS IN CARE IN ELIMINATION OF MOTHER TO CHILD TRANSMISSION OF HIV IN EASTERN UGANDA Gerald.
PMTCT 365 Days of Action to end the hidden violence against women and children Protecting Women early.
A MISSED OPPORTUNITY FOR PMTCT SERVICES: SUCCESSFUL ANTENATAL HIV SCREENING AND POOR LINKAGES TO HIV CARE AND TREATMENT Changala Mable, Sikazwe Izukanji,
Outcome of a Prevention of mother to child transmission (PMTCT ) programme following Implementation of prophylaxis for HIV infected pregnant women in Barbados:
Use of improved tracking of exposed infants during early infant diagnosis (EID) to reinforce PMTCT outcomes in a low resource setting. Lessons from East-central.
WHO 2013 Consultative Meeting Tawanna Hotel October 15, 2013.
 Efficacy of Nevirapine Administration on the Mother to Child Transmission of HIV using a modified HIVNET 012 regimen. M. A St John*, Alok Kumar*, Kelly.
Loss to follow-up of HIV-infected women after delivery: The Swiss Mother and Child HIV Cohort Study Karoline Aebi-Popp, Roger Kouyos, Barbara Bertisch,
CHILDREN and HIV.
Pediatrics HIV/AIDS and PMTCT research in Barbados: lessons learned for monitoring the epidemic and evaluating the interventions.   ALOK KUMAR, MD. Lecturer.
The Impact of Routine Counseling and Testing with an Opt-Out Strategy Compared to Voluntary Counseling and Testing in the Implementation of PMTCT Services.
Claire Gamble Friday 30th June 2017
USAID World Breastfeeding Week Webinar Series: Every day at 9-10AM EDT
Presentation transcript:

PMTCT program in Arua Uganda Lessons learned after 5 years of experience Experts Roundtable June 2008 Geneva

Arua PMTCT program (1) Started in January st ante-natal visit : HIV voluntary counselling & testing HIV+ enrolled in PMTCT program

Arua PMTCT program (2) National PMTCT protocol (2000 to 2005) – Mother : NVP at labour onset – Infant : AZT (1 wk) or NVP (<72 h) Follow-up – Cotri prophylaxis + feeding education – Infant formula (up to June 2004)

Arua PMTCT program (2) National PMTCT protocol (2000 to 2005) – Mother : AZT from 36 wk or NVP at labour onset or ART – Infant : AZT (1 wk) or NVP (<72 h) Follow-up – Cotri prophylaxis + feeding education – Infant formula (up to June 2004) Pregnant women in ANC n= Pre-test counseling n= (72%) HIV-test refused  Routine ANC n=3 088 (14%) HIV-tested n= (62%) HIV– n= (95%) HIV + n=1 037 (5%) PMTCT n=517 (49.8%) Routine ANC n=520 (50.2%)

Objectives Describing characteristics of mothers & infants Quantifying and describing reasons for loss to follow-up (LTFU) Estimating HIV transmission Evaluate the performance of the PMTCT program of Arua by:

Methods (1) Retrospective cohort analysis – Inclusion: Women enrolled in PMTCT between July 2000-July 2005 Description of infant outcomes Active tracing of LTFU Cross-sectional survey – Interview of caregivers (reasons for LFU) – Clinical examination and HIV testing for infants

Methods (2) Survival Analyses (Kaplan-Meier) HIV transmission – HIV testing for children alive – HIV-related deaths*: severe infection or persistent diarrhoea AND > 1 HIV-related symptom at last MCH visit Risk factors for HIV-transmission (multiple logistic regression) * Ghent Int. Working Group on MTCT of HIV

Results: PMTCT Program (July 2000 – July 2005) Enrolled: – Mothers (N=517) – Infants (N=567) Infant outcomes (n=567)

Results: PMTCT Program (July 2000 – July 2005) Enrolled: – Mothers (N=517) – Infants (N=567) Cross-sectional survey – Mothers (N= 327, 63%) – Infants (N= 368, 65%) Infant outcomes (n=567)

Maternal characteristics at PMTCT enrolment (N=327) 32 (10) On ART 368 [ ]Median CD4+ cells/ml; n=201 [IQR] 5 (2) 164 (50) 144 (44) 13 (4) WHO stage (%) Asymptomatic Stage I/II Stage III Stage IV 4 (1) 72 (22) 233 (71) 18 (6) Trimester of pregnancy (%) First Second Third At/after birth 28 [25-32]Median age (yr) [IQR]

Newborn characteristics (N=368) Place of delivery (%) Arua Regional Hospital Home/on the way Health centre/other hospital 280 (76) 70 (19) 17 (5) Female (%)182 (50) Median weight, kg [IQR] (n=334) 3 [ ] Timing of ARV start for mother ART ≥ 3 months before birth ART < 3 months before birth NVP prophylaxis at birth AZT prophylaxis at birth None 44 (12) 21 (6) 253 (69) 19 (5) 24 (7) ARV post-partum prophylaxis (%) NVP single dose AZT one week None 288 (78) 12 (3) 65 (18)

Follow-up characteristics of infants (N=368) Median nb of post-natal consultation visits [IQR]4 [0 -9] Type of feeding received (%) Exclusive breastfeeding Exclusive infant milk formula Mixed feeding 103 (29) 96 (27) 154 (44) Median age at weaning start [IQR] (n=353)6 [4 - 6]

HIV transmission 8.3% (24 / 288) of children were HIV+ Overall transmission = 15.5% (57 / 367)

Risk factors for MTC HIV transmission * Characteristics HIV+ (%) Multivariate analysis OR (95% CI)p-value Age (yr) >=25 vs. <259 (9)0.4 ( )0.09 WHO stage 3/4 vs 1/27 (9)0.7 ( )0.45 CD4+ (cells/mm3) >=350 vs. < (14)1.7 ( )0.38 Home delivery/on the way 7 (26) 3.7 ( )0.03 Females 4 (6)0.4 ( )0.15 ARV prophylaxis vs. none13 (10) 3.6 ( ) 0.17 Type of feeding Infant formula vs. breast feeding Mixed feeding vs. breast feeding 2 (6) 10 (15) 1.14 ( ) 2.6 ( ) 0.30 Weaning at 6 months 7 (14) 1.5 ( ) 0.46 *Among children tested for HIV (n=288) Mother Child

Infant survival 33 / 72 deaths were HIV-related Most frequent causes of death –Acute or chronic diarrhoea (34.7%) –Respiratory tract infections (20.8%) 0.81 (95% 0.77 – 0.85)

Mother/baby pair LTFU Median time at LTFU was 1 month (IQR : 0 – 5) Reasons for LFU (n=197) – 30% mothers' ignorance of the importance of FU – 27 % infant death – 13 % discouraged by the partner – 12 % address change

Discussion (1) Mothers 40% women refused to be tested Among the HIV +, 50% refused to be enrolled in the PMTCT Among the enrolled women, 50% drop out First visit in third trimester of pregnancy 50% accessed ANC in earlier HIV disease 21% home delivery

Discussion (2) Infants 18% did not receive PMTCT prophylaxis HIV transmission rate reduced from 35% to 15.5% Mother/baby pairs LTFU 53% LTFU before tracing Main reasons for LTFU = mother’s ignorance of importance of FU & infant death BUT 30% of pairs untraced

Recommendations Improve the message delivered to mothers at enrolment Increase resources for PMTCT ( HR, logistics…) Reconsider Feeding strategy Early diagnosis and treatment for children

Acknowledgments Ugandan Ministry of Health in Arua and Kampala MSF team in Arua and Kampala Epicentre in Kampala and Paris CDC laboratory in Entebbe (Ugandan Virus Institute)

ARUA REFFERAL REGIONAL HOSPITAL PMTCT From May 2007 to end of February 2008

Organigram Flow of patient PMTCT AN +HIV f/up Mother and child f/up until 1 year ANC VCT HIV clinic Women became pregnant Maternity ward Labour suite Home delivery Mother 1year after delivery Child+ after 1 year

Treatment protocol Antepartum treatment Labour treatment Postpartum treatment Child treatment Pregnant women Cd4<350 HAART AZT 1ml bd 7 days ( *4 weeks if the mother begins treatment less than 1 month before delivery) Pregnant women Cd4>350 AZT 300mg bd >28 WA Sd NVP 200mg + (AZT-3TC) (600/300) stat Tail AZT-3TC (300/150) bd 7 days Sd NVP 0.6ml + AZT 1ml bd 7 days ( or *)

Data from ANC from May 2007 to end of February % women accept to be tested 75% of mother tested HIV+ are enrolled in PMTCT HIV prevalence at ANC is 4 % during the period Total first ANC9923 Total pregnant women tested6252 Total tested HIV +256 Total enrolled in PMTCT191

Mothers enrolled in PMTCT May 2007 to End of February 2008 (1) Weeks in pregnancyTotal (%) < 28 weeks273 (54%) > 28 weeks and < 36 weeks83 (16%) > 36 weeks48 (9%) With baby99 (20%) Total503 (100%)

Mothers enrolled in PMTCT May 2007 to End of February 2008 (2) Median CD4 : 448 /mm 3 WHO staging (from ANC only ) Total (%) Stage 1125 (64%) Stage 238 (20%) Stage 319 (10%) Stage 49 (5%) Total191 (100%) 85%

Mothers enrolled in PMTCT May 2007 to End of February 2008 (3) 8% are lost to follow-up 40% are on ARVs (10% in ) 62% of the mothers enrolled in PMTCT are coming from HIV clinic Total (%) Total enrolled503 (100%) death1 (0%) Lost of follow-up41 (8%) Transfered4 (1%) Followed with no ttt252 (50%) Followed on ARV203 (40%) Unspecified2 (0%)

Prophylaxis and treatment (1) Ante partum drugs% HAART40% AZT (> 28 weeks)33% None25% Unknown1.5% Intra partum drugs HAART40% NVP+ (AZT/3TC)13% AZT+NVP4% Stat NVP10% AZT13% None17% 73% 57%

Prophylaxis and treatment (2) Post partum prophylaxis HAART43% Tail AZT/3TC19% None20% Baby prophylaxis Stat NVP+ AZT37% Stat NVP17% None26%

Location of delivery May 2007 to End of February 2008

Feeding Option PMTCT May 2007 to End of February 2008

Outcome of children Will need to wait 2009 regional meeting…. Thanks

WHO stage & CD4 at PMTCT enrolment <350 CD4 cells/ml >=350 CD4 cells/ml No CD4Total Stage 1&237 (21.9) 61 (36.1) 71 (42.0) 169 Stage354 (37.5) 44 (30.5) 46 (32.0) 144 Stage4 2 (15.4) 3 (23.1) 8 (61.5) 13 No staging0 (0) 0 (0) 1 (100) 1 Total 93 (28.4) 108 (33.0) 126 (38.6) 327

Maternal characteristics at follow-up (N=327) Partner/family aware of HIV status : 297 (90.8%) Partner aware of PMTCT enrolment : 242 (74.0%) Participation in PMTCT  No problems : 279 (85.3%)  Separation/divorce : 22 (6.7%)  No male involvement/conflict : 15 (4.6%)  Family stigma/conflict : 9 (2.8%)  Other : 2 (0.6%)